Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Augustine Therapeutics is currently overseeing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and is situated within 1 distinct art unit. Such a concentrated profile indicates that the company's immediate patent office activity is focused on a specific pharmaceutical or biotechnological advancement.
The busiest examiner identified in the data is WILLIS, DOUGLAS M, who is managing 1 pending office action. As this is the only pending action for the company, the examiner's perspective will be the sole factor in the current prosecution phase. The presence of only 1 distinct examiner and 1 distinct art unit suggests a very targeted approach to intellectual property within the Biotechnology & Pharmaceuticals sector.
For practitioners, the fact that 1 pending office action is the only active matter means that all resources can be directed toward this single interaction. WILLIS, DOUGLAS M represents the only point of contact at the patent office for these pending matters. This simplicity in the prosecution landscape allows for a highly specialized response to the 1 pending office action within the designated art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723237 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723237 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723237 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | WILLIS, DOUGLAS M | 1624 | §112DP | Non-Final OA | — | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAugustine Therapeutics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Douglas M Willis has the most, with 1 of Augustine Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
